Randomized, Placebo-controlled, Double-blind Study of 2LHERP® in Orofacial Herpes Infections.
Status:
Recruiting
Trial end date:
2023-03-09
Target enrollment:
Participant gender:
Summary
Herpes simplex virus (HSV) infection is very common, as most people will experience herpetic
infection during their lifetime. The most common manifestation of HSV infection is sores
which may appear at any age.
No specific antiviral therapy is available to totally cure herpetic infections and today,
there is no treatment that allows the definitive eradication of the virus.
The 2LHERP® has been available for more than 20 years, and has received a marketing
authorization in Belgium by the FAMHP. It is used as an immune regulator in the treatment of
herpetic infections. Since 2LHERP® has been made available, clinical observational data
collected on treated patients have shown the beneficial effect on the disappearance of
herpetic recurrences.
The purpose of this placebo-controlled trial is to evaluate the efficacy of 2LHERP® on the
treatment of herpetic infections in adults.